September 30, 2015 5:04pm

 

Q3 and September, if today was your last day and tomorrow was too late; aren’t you glad to say goodbye? The lyrics speak; “let nothing stand in your way, ‘cause the hands of time are never on your side”.  

Subscription required: http://www.regmedinvestors.com/user/register

 

Make RegMed Investors your daily destination. We’ve gathered and sifted through news and share pricing data you need in one convenient spot.

 

Stocks mention in the closing bell report: AxoGen (AXGN), bluebird bio (BLUE), Capricor (CAPR), Intrexon (XON), Applied Genetic Technologies (AGTC),  uniQure (QURE) , Bellicum (BLCM), Fate Therapeutics (FATE), Mesoblast ADR (USOTC: MBLTY), Organovo (ONVO), Verastem (VSTM), Vericel (VCEL), Juno Therapeutics (JUNO), Kite Pharma (KITE), Regenxbio (RGNX), Neuralstem (CUR) and Asterias (NYSEMKT: AST),

 

 

 

Major averages ended with solid gains Wednesday as the NASDAQ snapped a six-session losing streak. The NASDAQ jumped 2.3%, the S&P 500 added 1.9% and the Dow rose 1.5%. The Russell 2000 index of small-cap stocks rallied 1.7%. Preliminary data showed NYSE and NASDAQ volume coming in slightly lower than Tuesday's levels!

The NASDAQ closed UP +102.84 or +2.28% to 4,620.17 and the DOW was UP +235.57 or +1.47% to 16,284.70.

 

 

A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector:

iShares Nasdaq Biotechnology ETF (IBB) came off highs to trade about 4% higher, holding in a bear market, or more than 20% below its 52-week high, after a sharp sell-off in recent weeks.

  • SCGT & RM equities opened positive with an A/DL of 36/22 and 5 flats followed by a positive mid-day A/DL of 26/15 and 2 flats;
  • The 2 pm numbers dropped the sector with a positive A/DL of 28/12 and 3 flats while the 3 pm hour solidified the continuing positive A/DL of 28/13 and 2 flats culminating in a positive close of A/DL of 30/11 and 2 flats. 

The CBOE Volatility Index (VIX) - the best gauge of fear in the market, traded near 24, down from yesterday’s near 27.

  • A week and a half into the downdraft and with the EFTs and indexes running amuck poised to try to break up but, will end up lower still. 

There is enough evidence to suggest that even though share pricing has spiked to the upside, it is most likely to dive lower although it is unlikely that we are going to see the downdrafts of the previous week!

  • Higher volume declines followed up by lower-volume gains doesn't exactly strengthen the base, but Wednesday's gains were good news for a lot of battered portfolios.

 

 

Dosing the sector – 43 Patients:

  • Open: POSITIVE with 2 decliners, 36 advancers and 5 flats;
  • Mid-day (12:30 pm) POSITIVE with 15 decliners, 26 advancers and 2 flats;
  • 2 pm: NEGATIVE with 12 decliners, 28 advancers and 3 flat;
  • 3 pm: NEGATIVE with 13 decliners, 28 advancers and 2 flats;
  • Closing bell: NEGATIVE with 11 decliners, 30 advancers and 2 flats

 

 

The week’s indexes in review:

  • The NASDAQ Biotechnology index (NBI) closed UP on Wednesday +135.76 or +4.48% after Tuesday’s decline of -17.46 or -0.57 following Monday’s decline of -195.27 or -6.02%;
  • The iShares Nasdaq Biotechnology ETF (IBB) closed UP on Wednesday +12.72 or +4.39% after Tuesday’s decline of -1.13 or -0.39% following Monday’s decline of -19.63 or -6.33%;
  • The Russell 2000 (IWM) closed UP on Wednesday +1.67 or +1.55% after Tuesday’s decline of  -0.77 or -0.71% following Monday’s decline of -3.12 or -2.80%;
  • The SPDR SD&P Biotech ETF (XBI) closed UP on Wednesday +2.26 or +3.77% after Tuesday’s decline of  -2.63 or -4.20% following Monday’s decline of -4.85 or -7.19%;
  • The CBOE Volatility Index (.VIX) closed Wednesday near 24 after Tuesday’s near 27 following Monday’s above 28

 

 

A comparison of the closing bell patterns of advance/decline lines:

  • Last, Wednesday: 12/30;
  • Thursday: 17/23;
  • Friday: 2/40;
  • Monday: 4/38;
  • Tuesday: 5/34;
  • Today, Wednesday: 30/11

 

 

Wednesday’s trading indications: 7 hits/ 6 misses:

  • Applied Genetics Technology (AGTC) closed UP - hit;
  • AxoGen (AXGN) closed DOWN – miss;
  • Bellicum Pharma (BLCM) closed UP – hit;
  • bluebird bio (BLUE) closed DOWN – hit;
  • Capricor (CAPR) closed UP – miss but, I am still holding this share to lower pricing as a financing is due;
  • Fate Therapeutics (FATE) closed UP – hit;
  • Intrexon (XON) closed UP – hit;
  • Juno Therapeutics (JUNO) closed UP – miss;
  • Kite Pharma (KITE) closed UP – hit;
  • Mesoblast ADR (USOTC: MBLTY) closed DOWN – miss;
  • Organovo (ONVO) closed DOWN – miss;
  • Verastem (VSTM) closed UP – hit;
  • Vericel (VCEL) closed UP – miss, a financing is coming – be aware;

 

 

Who is UP?

  • Kite Pharma (KITE) closed up +$3.68 to $55.68;
  • Spark Therapeutics (ONCE) +$2.82 to $41.73;
  • Regenxbio (RGNX) +$2.51 to $22.03;
  • Intrexon (XON) +$2.41 to $31.80;
  • VistaGen (VSTA) closed UP +$2.00 to $10.00

 

 

Who is down - the lowest 5:

  • bluebird bio (BLUE) closed down -$1.39 to $85.55;
  • Mesoblast ADR (USOTC: MBLTY) -$1.09 to $11.30;
  • Neuralstem (CUR) closed down -$0.16 to $1.22;
  • Asterias (NYSEMKT: AST) -$0.08 to $3.86;
  • AxoGen (AXGN) closed down -$0.06 to $4.12

 

 

Who is flat?

  • ReNeuron (RENE.L) at $4.125
  • Sangamo (SGMO) at $5.64

 

 

The information included above as well as individual companies and/or securities mentioned should not be construed as investment advice, a recommendation and/or an indication of trading intent on behalf of any RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

By working closely with your financial advisor, ensures your portfolio supports long-term goals, time horizon and tolerance for risk

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.